PD-L1, tumor mutational burden (TMB), and tumor immune microenvironment (TIME) are considered to be biomarkers for predicting the efficacy of immune checkpoint inhibitors in NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.